Journal article icon

Journal article

Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c trial

Abstract:

PURPOSE: To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG 9313.

METHODS: Four hundred twenty-five centrally determined patient cases with TNBC from S9313 were identified. DDIR signature was perform...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
Expand authors...
Publisher:
American Society of Clinical Oncology Publisher's website
Journal:
Journal of Clinical Oncology Journal website
Volume:
37
Issue:
36
Pages:
3484-3492
Publication date:
2019-10-28
Acceptance date:
2019-09-02
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
Pubs id:
1115982
Local pid:
pubs:1115982
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP